Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Oct
24
2023
Congress May Have a Vision for Psychedelic Regulation in the US Epstein Becker & Green, P.C.
Oct
24
2023
Stocking Naloxone in the Workplace: What Employers Need to Consider Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Oct
24
2023
Telehealth Update: DEA Extends Flexibility in Prescribing Controlled Substances via Telehealth Through 2024 Mintz
Oct
24
2023
FDA Updates Guidance Regarding Scientific Communications to HCPs about Unapproved Uses of Approved/Cleared Medical Devices and Drugs Nelson Mullins
Oct
24
2023
DEA Issues Second Temporary Extension of COVID-19 Telemedicine Prescribing Flexibilities, Through 2024 Epstein Becker & Green, P.C.
Oct
24
2023
DEA Further Extends COVID-19 Telemedicine Prescribing Flexibilities through December 31, 2024 Robinson & Cole LLP
Oct
24
2023
EPA Announces Winners of the 2023 Green Chemistry Challenge Awards Bergeson & Campbell, P.C.
Oct
24
2023
FDA Seeks to Increase Regulatory Oversight of Laboratory Developed Tests ArentFox Schiff LLP
Oct
24
2023
Lawsuit Alleges Panera’s Caffeinated Lemonade Caused Death Keller and Heckman LLP
Oct
24
2023
In This Case, "Primarily" Means A Small Fraction Allen Matkins Leck Gamble Mallory & Natsis LLP
Oct
23
2023
OCR Cybersecurity Newsletter Emphasizes Significance of HIPAA Sanction Policies Mintz
Oct
23
2023
California Bans Four Federally Cleared Additives From Use in Food K&L Gates
Oct
23
2023
FDA Deputy Commissioner for Human Foods Expresses Commitment to Human Foods Program Framework Keller and Heckman LLP
Oct
23
2023
Safeguarding AI Innovation in Stem Cell Therapy Foley & Lardner LLP
Oct
22
2023
NNI Nanoinformatics Conference and U.S.-EU NanoEHS COR Workshop Will Be Held in November 2023 Bergeson & Campbell, P.C.
Oct
20
2023
Dirty Steel-Toe Boots, Episode 20: Marijuana in the Workplace [Podcast] Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Oct
20
2023
APHIS Releases Revised Draft and Response to Comments on Guide for Submitting Permit Applications for Microorganisms Developed Using Genetic Engineering Bergeson & Campbell, P.C.
Oct
19
2023
APHIS Releases Revised Guidance for Genetically Engineered Microorganism Applications Keller and Heckman LLP
Oct
18
2023
FDA’s Proposed Rule on LDT Regulation and the Debate over Agency Deference Sheppard, Mullin, Richter & Hampton LLP
Oct
18
2023
Behavioral Health Law Ledger | October 2023 Greenberg Traurig, LLP
Oct
18
2023
California Attorney General Issues Enforcement Advisory Letter to Warn Companies of Responsibility to Disclose Presence of PFAS Bergeson & Campbell, P.C.
Oct
18
2023
DOJ's Consumer Protection Branch Continues Civil Enforcement Against Pharmacies, Pharmacists for Opioid Dispensing Barnes & Thornburg LLP
Oct
18
2023
OECD Tour de Table Includes Information on U.S. Developments on Human Health and Environmental Safety of Nanomaterials Bergeson & Campbell, P.C.
Oct
18
2023
FDA Issues New Enforcement Policy for Face Masks and Barrier Face Coverings ArentFox Schiff LLP
Oct
18
2023
Califf Provides Update on Front-of-Package Labeling Keller and Heckman LLP
Oct
17
2023
CPSC Signals its Regulatory Interest in PFAS Foley & Lardner LLP
Oct
17
2023
Tele-Prescribing Flexibilities Extended Again in Second Temporary Rule Sheppard, Mullin, Richter & Hampton LLP
Oct
17
2023
Revamping Cosmetics Safety and Regulation: Updates from FDA on Regulatory Changes under MOCRA. Squire Patton Boggs (US) LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins